Tech Company Financing Transactions
Umecrine Cognition Funding Round
Umecrine Cognition closed a $2.6 million funding round on 7/14/2025. Investors included Karolinska.
Transaction Overview
Company Name
Announced On
7/14/2025
Transaction Type
Debt
Amount
$2,600,000
Round
Undisclosed
Investors
Proceeds Purpose
The funding will be used to finance the ongoing clinical trial of golexanolone in primary biliary cholangitis as well as operational expenses.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Nanna Svartz väg 6A
Solna, 171 65
Sweden
Solna, 171 65
Sweden
Phone
Website
Email Address
Overview
Umecrine Cognition is developing a completely new type of drug for neurological disorders in the brain that can occur as a result of a number of underlying diseases and lead to severely reduced cognition and alertness. The results from an internationally recognized clinical phase 2 study indicate that the company's most advanced drug candidate, golexanolone, improves brain signaling and cognition and alertness in patients with hepatic encephalopathy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Viktor Drvota
Browse more venture capital transactions:
Prev: 7/13/2025: Emerging Markets Global Advisory (EMGA) venture capital transaction
Next: 7/14/2025: Lucidya venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs